Top Page
Somnomed Limited
(Sydney:SOM)
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Somnomed Limited Business Overview & Revenue Model
Somnomed Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.25M | 111.49M | 91.65M | 83.62M | 72.58M | 62.71M |
| Gross Profit | 57.29M | 66.73M | 55.13M | 45.77M | 39.15M | 33.90M |
| EBITDA | 1.44M | 1.58M | -2.33M | 698.39K | 820.83K | 3.57M |
| Net Income | -6.00M | -3.46M | -12.24M | -8.00M | -4.44M | -1.19M |
Balance Sheet | ||||||
| Total Assets | 74.99M | 80.97M | 69.80M | 62.49M | 58.09M | 56.17M |
| Cash, Cash Equivalents and Short-Term Investments | 18.50M | 17.29M | 16.18M | 11.96M | 15.64M | 21.11M |
| Total Debt | 5.91M | 8.03M | 6.72M | 23.51M | 12.01M | 8.91M |
| Total Liabilities | 27.53M | 34.58M | 24.78M | 40.09M | 30.31M | 24.01M |
| Stockholders Equity | 47.46M | 46.39M | 45.02M | 22.40M | 27.79M | 32.16M |
Cash Flow | ||||||
| Free Cash Flow | 809.32K | 5.36M | -7.72M | -10.29M | -6.93M | -1.43M |
| Operating Cash Flow | 2.32M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M |
| Investing Cash Flow | -4.52M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M |
| Financing Cash Flow | 6.91M | -3.38M | 16.68M | 6.61M | 2.09M | -6.80M |
Somnomed Limited Technical Analysis
Somnomed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $178.91M | -51.25 | -7.26% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$61.51M | -46.38 | -6.35% | ― | 2.23% | -263.16% | |
48 Neutral | $73.35M | ― | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Somnomed Limited Corporate Events
SomnoMed Limited announced that the Australian Stock Exchange has advised the company that it is no longer required to submit quarterly activity and cashflow reports. As a result, SomnoMed will transition to half-year and full-year reporting after releasing its Q1 FY26 update on 30 October 2025. This change is expected to streamline the company’s reporting process and may impact how stakeholders track the company’s financial performance.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited’s recent presentation at the Canaccord Drug & Devices Conference highlights the company’s ongoing efforts to revolutionize the sleep medicine industry. While the document includes forward-looking statements about future sales and operational advancements, it emphasizes the speculative nature of the company’s securities and the inherent risks involved. Stakeholders are advised to consider their personal financial circumstances before investing, as the company does not guarantee returns or dividend payments.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
Somnomed Limited has announced the issuance of unquoted equity securities, including zero exercise price options expiring in 2030 and 2031, as part of its employee incentive scheme. This strategic move is aimed at enhancing employee engagement and aligning their interests with the company’s long-term growth objectives, potentially strengthening its market position and operational capabilities.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited has released a proxy form for its upcoming Annual General Meeting scheduled for November 27, 2025. Shareholders are encouraged to appoint proxies and provide voting directions on various items of business, including the adoption of the Remuneration Report and the election or re-election of directors. The release outlines the necessary steps for appointing a proxy, directing votes, and lodging the proxy form, emphasizing the importance of timely submission to ensure participation in the meeting.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited has announced its Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. The meeting will address several key items including the consideration of financial statements, adoption of the remuneration report, election and re-election of directors, and the issuance of options under the Non-Executive Share Option Plan 2021. Shareholders are encouraged to review proxy forms and voting exclusions are in place for certain resolutions, particularly those involving key management personnel.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited has announced a change in the director’s interest, with Benjamin Gisz reducing his indirect shareholding in the company. The transaction involved the sale of 13,211,430 ordinary shares at $0.70 per share, resulting in Gisz holding 54,504,649 ordinary shares post-transaction. This change reflects a significant adjustment in the director’s investment, potentially impacting the company’s market perception and investor confidence.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.99 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited announced the successful completion of a block trade involving 16,071,430 shares at $0.70 per share on the ASX. This transaction included shares from the SomnoMed employee share trust and TDM Growth Partners, with TDM’s stake in SomnoMed reducing from 31.3% to 25.0%. The sale aimed to diversify SomnoMed’s share register and improve liquidity without diluting existing shareholders, attracting participation from new and existing institutional and retail shareholders.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.99 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited is an Australian company specializing in the production and commercialization of oral appliances for the treatment of sleep-related disorders, particularly obstructive sleep apnea (OSA). The company operates globally, with a strong presence in Europe, North America, and Asia Pacific.
SomnoMed Limited has released its Corporate Governance Statement in line with the 4th Edition of the ASX Corporate Governance Principles and Recommendations. The statement outlines the company’s adherence to these principles, emphasizing the role of its Board in ensuring effective governance, strategic direction, and accountability. The Board’s responsibilities include overseeing management, approving strategic plans, and ensuring risk management frameworks are in place. The statement also details the procedures for appointing directors and senior executives, highlighting the importance of transparency and informed decision-making for shareholders.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited has released its full-year 2025 results, emphasizing its commitment to treatment-focused, technology-driven solutions. The announcement highlights the speculative nature of its securities, cautioning investors about potential risks and uncertainties that could impact future performance. The company advises careful consideration of its securities in light of personal financial circumstances.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited reported a strong financial performance for FY25, with a 21.6% increase in revenue to $111.5 million, surpassing market guidance. The company achieved significant milestones, including treating one million patients and expanding its facility capacity to support future growth. The North American and European markets were key contributors to this success, with Europe remaining the largest revenue-generating region. The company’s strategic focus on increasing capacity and reducing backlog positions it well for sustained growth and value delivery.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited has released its 2025 Full Year Report, highlighting a significant 21.6% increase in revenue from ordinary activities to $111.5 million. Despite reporting a loss from ordinary activities after tax of $3.5 million, this marks a substantial improvement of 71.8% compared to the previous year. The company announced that no dividend will be paid for the year ended 30 June 2025, reflecting a strategic focus on reinvestment and growth. The results suggest a positive trajectory in financial performance, potentially enhancing SomnoMed’s positioning in the sleep-related breathing disorder treatment industry.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
SomnoMed Limited announced that its FY25 Financial Results and Investor Presentation will be released to the ASX on August 28, 2025. Co-CEOs Karen Borg and Amrita Blickstead, along with CFO Ye-Fei Guo, will host a webinar to discuss the results and engage in a Q&A session with investors. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.